Skip to main content

Transfer of multivirus-specific T-cells following transplantation

Objective

Allogeneic stem cell transplantation (HSCT) is a curative treatment for a variety of diseases. Viral infections such as Cytomegalovirus (CMV), Epstein-Barr-virus (EBV) and Adenovirus (AdV) are major unsolved problems for patients receiving allogeneic HSCT. Refractory viral infections post-HSCT are rare, life-threatening conditions due to the deficient T-cell response post-SCT and lacking effective treatment options. Protective T-cell immunity could be restored by means of a procedure known as adoptive T-cell transfer. Although cellular immunotherapy is considered a major recent breakthrough in medicine, none of the cellular treatment approaches has yet become a standard treatment. The reason for this limited translation into daily clinical practice is the lack of controlled, prospective clinical trials investigating efficacy of immunotherapy. The objective of TRACE is to bring adoptive T-cell transfer into clinical routine as a life-saving, curative and safe treatment for refractory viral infection post-HSCT. TRACE is a multi-national clinical trial to prove efficacy and safety of adoptive T-cell transfer in immune-compromized individuals. For the first time, this trial will show that a unique individualized immunotherapy could be included into evidence based clinical routine in rare diseases. Regulatory and structural hurdles will be overcome by standardized GMP-procedures. It will be a major milestone in the development of medicine and health economics to bring such a unique personalized treatment approach into a clinical efficacy trial. The consortium provide excellence in immunotherapy through partners from basic, clinical and industrial research and GMP facilities, with proven qualification and expertise in the field of HSCT, GMP manufacturing and adoptive T-cell transfer. It will bring medicine towards physiological self-protection of the human body instead of cost-intensive toxic agents and will thereby improve survival and quality of life.

Call for proposal

H2020-SC1-2016-2017

See other projects for this call

Sub call

H2020-SC1-2017-Two-Stage-RTD

Coordinator

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Net EU contribution
€ 1 641 600,00
Address
Geschwister Scholl Platz 1
80539 Muenchen
Germany

See on map

Region
Bayern Oberbayern München, Kreisfreie Stadt
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00

Participants (9)

MILTENYI BIOTEC GMBH

Participation ended

Germany
Net EU contribution
€ 77 652,50
Address
Friedrich Ebert Strasse 68
51429 Bergish Gladbach
Region
Nordrhein-Westfalen Köln Rheinisch-Bergischer Kreis
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 0,00
OSPEDALE PEDIATRICO BAMBINO GESU
Italy
Net EU contribution
€ 442 025,00
Address
Piazza Sant Onofrio 4
00165 Roma

See on map

Region
Centro (IT) Lazio Roma
Activity type
Research Organisations
Other funding
€ 0,00
ACADEMISCH ZIEKENHUIS LEIDEN
Netherlands
Net EU contribution
€ 350 600,00
Address
Albinusdreef 2
2333 ZA Leiden

See on map

Region
West-Nederland Zuid-Holland Agglomeratie Leiden en Bollenstreek
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00
CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE NANCY
France
Net EU contribution
€ 388 750,00
Address
Avenue Mar De Lattre Tassigny 29
54035 Nancy Cedex

See on map

Region
Grand Est Lorraine Meurthe-et-Moselle
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00
UNIVERSITY OF NEWCASTLE UPON TYNE
United Kingdom
Net EU contribution
€ 245 250,00
Address
Kings Gate
NE1 7RU Newcastle Upon Tyne

See on map

Region
North East (England) Northumberland and Tyne and Wear Tyneside
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00
UNIVERSITEIT GENT
Belgium
Net EU contribution
€ 370 300,00
Address
Sint Pietersnieuwstraat 25
9000 Gent

See on map

Region
Vlaams Gewest Prov. Oost-Vlaanderen Arr. Gent
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00
ORION CLINICAL SERVICES LTD
United Kingdom
Net EU contribution
€ 2 099 005,00
Address
Bath Road 7
SL13UA Slough

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
South East (England) Berkshire, Buckinghamshire and Oxfordshire Berkshire
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 0,00
FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON (VHIO)
Spain
Net EU contribution
€ 254 545,00
Address
Calle Nazaret 115-117
08035 Barcelona

See on map

Region
Este Cataluña Barcelona
Activity type
Research Organisations
Other funding
€ 0,00
MILTENYI BIOTEC BV & CO KG
Germany
Net EU contribution
€ 130 272,50
Address
Friedrich Ebert Strasse 68
51429 Bergisch Gladbach

See on map

Region
Nordrhein-Westfalen Köln Rheinisch-Bergischer Kreis
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 0,00